Nicotine metabolite ratio as a predictor of CYP2A6 phenotypic activity.

被引：0
|
作者：
Dempsey, DA [1 ]
Tutka, P [1 ]
Jacob, P [1 ]
Benowitz, NL [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P24 / P24
页数：1
相关论文
共 50 条
  • [41] The influence of CYP2A6 polymorphisms and cadmium on nicotine metabolism in Thai population
    Apinan, Roongnapa
    Tassaneeyakul, Wichittra
    Mahavorasirikul, Wiratchanee
    Satarug, Soisangwang
    Kajanawart, Sirimas
    Vannaprasaht, Suda
    Ruenweerayut, Ronnatrai
    Na-Bangchang, Kesara
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2009, 28 (03) : 420 - 424
  • [42] Determination of CYP2A6 Activity in the US Population by Use of a Caffeine Metabolite Ratio in Spot Urine Samples: NHANES 2009-2010
    Pao, Ching-I
    Sternberg, Maya R.
    Rybak, Michael
    FASEB JOURNAL, 2017, 31
  • [43] Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for CYP2B6 activity.
    Kharasch, E. D.
    Mitchell, D.
    Coles, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S35 - S35
  • [44] CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence
    Akrodou, Yawo Mawuli
    SCIENTIFICA, 2015, 2015 : 1 - 7
  • [45] Nicotine metabolism:: the impact of CYP2A6 on estimates of additive genetic influence
    Swan, GE
    Benowitz, NL
    Lessov, CN
    Jacob, P
    Tyndale, RF
    Wilhelmsen, K
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (02): : 115 - 125
  • [46] Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6
    Yokoi, Tsuyoshi
    DRUG METABOLISM REVIEWS, 2006, 38 : 10 - 11
  • [47] A pilot study characterizing two novel CYP2A6 alleles, CYP2A6*7 and CYP2A6*8, in vivo.
    Xu, C
    Rao, Y
    Xu, B
    Hoffmann, E
    Sellers, EM
    Tyndale, RF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P35 - P35
  • [48] A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo
    Al Koudsi, Nael
    Ahluwalia, Jasjit S.
    Lin, Shih-Ku
    Sellers, Edward M.
    Tyndale, Rachel F.
    PHARMACOGENOMICS JOURNAL, 2009, 9 (04): : 274 - 282
  • [49] Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme—an in silico approach
    M Rahnasto
    C Wittekindt
    R O Juvonen
    M Turpeinen
    A Petsalo
    O Pelkonen
    A Poso
    G Stahl
    H-D Höltje
    H Raunio
    The Pharmacogenomics Journal, 2008, 8 : 328 - 338
  • [50] Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted
    Yamanaka, H
    Nakajima, M
    Nishimura, K
    Yoshida, R
    Fukami, T
    Katoh, M
    Yokoi, T
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 22 (05) : 419 - 425
12345